Hamid, O., Chiappori, A. A., Thompson, J. A., Doi, T., Hu-Lieskovan, S., Eskens, F. A. L. M., Ros, W., Diab, A., Spano, J.-P., Rizvi, N. A., Wasser, J. S., Angevin, E., Ott, P. A., Forgie, A., Yang, W., Guo, C., Chou, J., & El-Khoueiry, A. B. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(10), e005471. https://doi.org/10.1136/jitc-2022-005471